Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
This article was originally published in The Pink Sheet Daily
Executive SummaryAbility of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.